RESTORE Study of FT218

If you or your child are over 16 and have been diagnosed with narcolepsy, you may qualify for the RESTORE research study. Managing your narcolepsy symptoms is […]

Avadel Pharmaceuticals Announces Results from its Phase 3 Trial of Once-Nightly FT218

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation […]